About
PRAME
PRAME is a target expressed in more than 50 cancers. Immatics is the global leader in precision targeting of PRAME and has the broadest PRAME franchise with the most PRAME indications and modalities.
The Immatics PRAME franchise currently includes three product candidates, two therapeutic modalities and a combination therapy that target PRAME: IMA203 PRAME cell therapy, IMA203CD8 PRAME cell therapy (GEN2), IMA402 PRAME bispecific, IMA203 in combination with Moderna’s PRAME adaptive immune modulating therapy.

Both modalities, ACTengine and TCER, demonstrate distinct attributes and clinical profiles. Each modality is designed to treat solid tumors at different stages of the disease and through different treatment regimens.
- ACTengine therapies are autologous cell therapies manufactured specifically for each patient with a short, approximately two-week, manufacturing turnaround time (“TAT”)[1]. We believe these therapies offer the advantage of single-dose infusions (“one-and-done”) and, based on the currently available clinical data, offer a higher potency than bispecifics. Thus, we believe ACTengine therapies are best positioned initially for monotherapy settings in the second-line and later where the medical need is highest due to a lack of alternative treatment options. They are currently deployed through specialized academic medical centers with the potential for outpatient administration in the future.
- TCER molecules are half-life extended (“HLE”) T cell engagers that are designed to be available “off-the-shelf” and distributed using standard pharmaceutical supply chain channels utilized for other biologics. TCERs will require repeat dosing (typically every two weeks) and may be suitable for administration in outpatient settings, in hospitals and in community centers. While bispecifics offer a classical off-the-shelf approach without personalized manufacturing, they are typically expected to be less potent than cell therapies. Thus, we believe TCERs are best positioned initially in earlier lines, including frontline or even adjuvant settings where they can be combined with standard-of-care.
[1] Turnaround time (TAT) is defined as the time for manufacturing and product release; i.e. time from receiving the leukapheresis at the company manufacturing site and the product being ready back for shipment to the treating clinical site. Screening procedures prior to leukapheresis, shipments and potential wait times at clinical sites for lymphodepletion and infusion are not included in the TAT.

In addition to our proprietary pipeline, we are also collaborating with world-leading partners to develop additional therapeutic programs covering ACT and Bispecifics. In these partnerships, Immatics seeks to evaluate and develop programs based on novel Immatics-derived targets in a variety of immunotherapeutic approaches.
From its research and development origins in Tübingen, Germany, to its cell therapy center in Houston, Texas, Immatics’ global team is committed to developing and advancing its therapeutic pipeline and collaboration programs to address significant unmet medical needs in oncology.